Scadden David 4
4 · AGIOS PHARMACEUTICALS, INC. · Filed Oct 2, 2025
Insider Transaction Report
Form 4
Scadden David
Director
Transactions
- Exercise/Conversion
Common stock
2025-09-30$18.09/sh+200$3,618→ 17,803 total - Sale
Common stock
2025-09-30$40.00/sh−200$8,000→ 17,603 total - Exercise/Conversion
Stock options (right to buy)
2025-09-30−200→ 27,307 totalExercise: $18.09Exp: 2032-06-21→ Common stock (200 underlying)
Footnotes (2)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]This option was granted on June 21, 2022. The shares underlying this option vest 100% one year from grant date.